The combination showed efficacy in a predominantly female, treatment-experienced, high-BMI population.
Joseph Merola, MD, MMSc
Advertisement
Professor and Chair of the Department of Dermatology and Professor of Internal Medicine in the Division of Rheumatic Diseases and in the Peter O'Donnell Jr. School of Public Health at UT Southwestern Medical Center in Dallas
Articles by Joseph Merola, MD, MMSc
Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.
Experts share what they anticipate most from the ongoing AMETHYST Phase 3 program and what approval of a first targeted therapy would mean for patients.
Experts explore how litifilimab's BDCA2-targeting mechanism maps onto CLE pathophysiology.
Experts discuss how an approved targeted therapy could restructure collaboration between dermatology and rheumatology.
Experts examine why the CLASI and CLA-IGA-R reflect the true burden of CLE.
With no targeted therapies approved in more than 70 years, new phase 2 AMETHYST data for litifilimab may signal a turning point for CLE.
Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.
Advertisement